EVAg

Middle East respiratory syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2

Middle East respiratory Syndrome coronavirus (MERS-CoV) was isolated in June 2012 from a man with acute pneumonia and renal failure.

C-terminal domain of the MERS CoV nucleprotein (239-413). Pure recombinant protein produced in E. coli and fused with a Avi tag and a Hexa-Hisitidine tag.

Serum obtained from rabbits challenged with MERS-CoV.

Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV infected dromedaries, MERS-CoV specific VHHs or nanobodies were produced. VHH-83 binds with exceptionally high affinity to the receptor binding domain of the viral spike protein. In vitro, this VHH efficiently blocks virus entry at picomolar concentrations

Serum obtained from dromedary camels immunized with a MVA vaccine expressing the spike protein and challenged with MERS-CoV.

HCAb-83 is a MERS-CoV specific camel/human chimeric heavy chain only antibody (HCAb) - composed of the camel VHH-83 linked to a human Fc domain lacking the CH1 exon Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV infected dromedaries, MERS-CoV specific VHHs or nanobodies were produced. VHH-83 binds with exceptionally high affinity to the receptor binding domain of the viral spike protein. In vitro, HCAb-83 efficiently blocks virus entry at picomolar concentrations

Panel consists of (cell-culture) RNA from different coronaviruses (HCoV-Nl63, HCoV-229E, HCoV-OC43, MERS-CoV and SARS-CoV) and is intended for use as control of specificity of molecular assays. This panel contains sufficient RNA for t least 5 experiments. "Disclaimer: Import permit may be needed in your country for SARS-CoV full virus RNA. If yes, please indicate so in your online enquiry". Product for Alphacoronavirus and Betacoronavirus. ------------------ NB: indicated price is only valid for non-profit laboratories. Commercial users will be contacted about pricing.

N-terminal domain of the MERS CoV nucleocapsid (1-164). Pure recombinant protein produced in E. coli. resuspended in HEPES buffer 10 mM pH 7.5, NaCl 300 mM.

N-terminal domain of the MERS CoV nucleocapsid (37-164, without the N-terminal intrinsically disordered region. Pure recombinant protein produced in E. coli. resuspended in HEPES buffer 10 mM pH 7.5, NaCl 300 mM

Expression plasmid for the N-terminal Domain of the MERS CoV Nucleocapsid coding sequence in fusion with a TRX/6-His tag encoding sequence at its 5'. For expression in E. coli

Expression plasmid for the Nterminal Domain of the MERS CoV Nucleocapsid coding sequence in fusion with a TRX/6-His tag encoding sequence at its 5'. For expression in E. coli

Real time detection kit for MERS CoV targeting the envelope gene (upE) that contains positive control, primers and probe.

Real time detection kit for MERS CoV targeting the "ORF 1a" containing positive control, primers and probe.

Training in Coronavirus reverse genetics to adapt novel techniques (ISA method) to large RNA viruses and compare different technologies under BSL-3 conditions

In this 2-day course the basic principles of routine virus neutralization and ELISA assays will be addressed by a combination of lectures, demonstration and hands-on training. Special attention will be given to quality control and assay validation. Topics include: cell culture, biosafety procedures, preparation of sera and virus stocks, ELISA and microarray formats, different virus neutralization tests using pseudotyped viruses and wildtype viruses, immunofluorescence staining of cells, calculation of titers, assay validation and quality control.

Anti-Middle East respiratory syndrome-related coronavirus NP protein polyclonal rabbit sera